// App-Quantinova.ai

5586 : Phase II study of cabozantinib in recurrent/metastatic endometrial cancer (EC): a study of the Princess Margaret, Chicago and California Phase II Consortia.

Researchers

Presenter

  • Neesha C. Dhani

Principal Investigators

  • Marcus O. Butler

  • Stephanie Lheureux

  • Julie Burnier

  • Michelle K. Wilson

  • Angela Jain

  • Mihaela C. Cristea

  • Stephen Welch

  • Waldo Jimenez

  • Daniela Matei

  • Katia Sonia Tonkin

  • Erica Stringer

  • Carolyn Johnston

  • Judy Quintos

  • Christine Tran

  • Katherine Karakasis

  • Lisa Wang

  • John Joseph Wright

  • Amit M. Oza

Medical Centers

  • Princess Margaret Cancer Centre, University Health Network, Division of Medical Oncology and Hematology, Toronto, ON, Canada

  • Juravinski Cancer Centre, Burlington, ON, Canada

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Fox Chase Cancer Center, Havertown, PA

  • Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA

  • London Regional Cancer Centre, London, ON, Canada

  • McMaster University, Hamilton, ON, Canada

  • Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

  • Cross Cancer Institute, Edmonton, AB, Canada

  • The University of Chicago Medical Center, Chicago, IL

  • University of Michigan, Ann Arbor, MI

  • PRINCESS MARGARET CANCER CENTRE, Toronto, ON, Canada

  • Universtiy Health Network, Toronto, ON, Canada

  • Universtiy Health Network, Toronto, ON, Canada

  • Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, ON, Canada

  • National Human Genome Research Institute, National Institutes of Health, Bethesda, MD

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Endometrial Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Cabozantinib

Outcome

  • N/A


Study Design

  • Multicenteric

  • Cohort

Phase

  • II

Study Id's

  • NCT01935934

Sponsors

  • N/A

Result

  • Final